Vincent Sainte-Rose
Vincent Sainte-Rose has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Alexis Daude
Laboratory of Microbiology, French Guiana University Hospital
1 shared publication- Alice Gilbert
Affiliations Institut National de la Santé et de la Recherche Médicale, Paris, France, Centre National de la Recherche Scientifique, Paris, France, MEMOLIFE Laboratory of excellence and Paris Science Lettre, Paris, France, Team Physiology and physiopathology of the gliovascular unit, Center for Interdisciplinary Research in Biology, Collège de France, Paris, France
1 shared publication - Chakir Bello
Laboratory of Biology and Molecular Typing in Microbiology, Faculty of Sciences and Techniques, University of Abomey-Calavi, Cotonou P.O. Box 1604, Benin
1 shared publication - Chloé Bertin
Department of Dermatology Centre Hospitalier de Cayenne Cayenne French Guiana
1 shared publication Daniel Selenge Kaozi
Laboratory of Microbiology, French Guiana University Hospital
1 shared publicationFabrice Chrétien
Affiliation Experimental Neuropathology Unit, Institut Pasteur, Paris, France
1 shared publication
Latest Publications
- Open Access
- 2 December 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (12) , e0035025
Susceptibility profile of Aeromonas spp. from clinical strains isolated in French Guiana
Aeromonas spp. are gram-negative bacilli of the Gammaproteobacteria class and Aeromonadaceae family. These bacteria are a public health challenge, particularly in South America. They harbor chromosomal β-lactamases belonging to classes B, C, and D, whose presence varies among species. This retrospective study aimed to evaluate the minimum inhibitory concentrations (MICs) of piperacillin-tazobactam (PTZ) and cefotaxime (CTX) for clinical strains of Aeromonas spp. A secondary objective was to assess the resistance profile of these strains to cefepime (FEP), aztreonam (AZT), ciprofloxacin (CIP), levofloxacin (LEV), and trimethoprim-sulfamethoxazole (SXT). The study was conducted at the Microbiology Laboratory of Cayenne Hospital (French Guiana) from January 2020 to December 2023. All isolated clinical Aeromonas strains, regardless of species or sample type, were included. In total, 99 strains were analyzed, comprising Aeromonas hydrophila ( n = 79), Aeromonas caviae ( n = 10), Aeromonas veronii ( n = 6), and other Aeromonas spp. ( n = 4). The median PTZ MIC was 0.5 mg/L for Aeromonas spp. overall, with six strains (6%) exhibiting MICs of >8 mg/L. For A. hydrophila , the median PTZ MIC was also 0.5 mg/L, lower than the median reported by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for strains of 4 mg/L. For CTX, the median MIC for all Aeromonas spp. was 0.064 mg/L, with four strains (4%) having MICs of >4 mg/L. The median ceftazidime (CAZ) MIC was 0.125 mg/L. No resistance to AZT was detected, and 3% high-dose susceptibility to FEP was found. Resistance rates to other antibiotics were low: 6% to CIP, 6% to LEV, and 6% to SXT. In conclusion, our study demonstrated low resistance rates in Aeromonas spp. to PTZ (6%), CTX (4%), and CAZ (4%). These findings suggest that PTZ and CTX could be effective against Aeromonas infections, despite the lack of established clinical breakpoints by EUCAST. IMPORTANCE: Aeromonas spp. are clinically significant, particularly in tropical climates. This study provides essential MIC distribution data for piperacillin-tazobactam and cefotaxime, offering valuable insights for guiding empirical treatment choices. Understanding these susceptibility patterns is crucial for optimizing antimicrobial therapy, particularly in regions with limited resistance surveillance and standardized guidelines. By analyzing a large collection of clinical isolates, our findings contribute to evidence-based decision-making for Aeromonas infections and emphasize the importance of continued surveillance of antimicrobial susceptibility. These findings suggest that PTZ and CTX may be therapeutic options for Aeromonas infections, supporting their potential use in clinical practice.
- 2 December 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (12) , e0035025
Open AccessSusceptibility profile of Aeromonas spp. from clinical strains isolated in French Guiana
Aeromonas spp. are gram-negative bacilli of the Gammaproteobacteria class and Aeromonadaceae family. These bacteria are a public health challenge, particularly in South America. They harbor chromosomal β-lactamases belonging to classes B, C, and D, whose presence varies among species. This retrospective study aimed to evaluate the minimum inhibitory concentrations (MICs) of piperacillin-tazobactam (PTZ) and cefotaxime (CTX) for clinical strains of Aeromonas spp. A secondary objective was to assess the resistance profile of these strains to cefepime (FEP), aztreonam (AZT), ciprofloxacin (CIP), levofloxacin (LEV), and trimethoprim-sulfamethoxazole (SXT). The study was conducted at the Microbiology Laboratory of Cayenne Hospital (French Guiana) from January 2020 to December 2023. All isolated clinical Aeromonas strains, regardless of species or sample type, were included. In total, 99 strains were analyzed, comprising Aeromonas hydrophila ( n = 79), Aeromonas caviae ( n = 10), Aeromonas veronii ( n = 6), and other Aeromonas spp. ( n = 4). The median PTZ MIC was 0.5 mg/L for Aeromonas spp. overall, with six strains (6%) exhibiting MICs of >8 mg/L. For A. hydrophila , the median PTZ MIC was also 0.5 mg/L, lower than the median reported by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for strains of 4 mg/L. For CTX, the median MIC for all Aeromonas spp. was 0.064 mg/L, with four strains (4%) having MICs of >4 mg/L. The median ceftazidime (CAZ) MIC was 0.125 mg/L. No resistance to AZT was detected, and 3% high-dose susceptibility to FEP was found. Resistance rates to other antibiotics were low: 6% to CIP, 6% to LEV, and 6% to SXT. In conclusion, our study demonstrated low resistance rates in Aeromonas spp. to PTZ (6%), CTX (4%), and CAZ (4%). These findings suggest that PTZ and CTX could be effective against Aeromonas infections, despite the lack of established clinical breakpoints by EUCAST. IMPORTANCE: Aeromonas spp. are clinically significant, particularly in tropical climates. This study provides essential MIC distribution data for piperacillin-tazobactam and cefotaxime, offering valuable insights for guiding empirical treatment choices. Understanding these susceptibility patterns is crucial for optimizing antimicrobial therapy, particularly in regions with limited resistance surveillance and standardized guidelines. By analyzing a large collection of clinical isolates, our findings contribute to evidence-based decision-making for Aeromonas infections and emphasize the importance of continued surveillance of antimicrobial susceptibility. These findings suggest that PTZ and CTX may be therapeutic options for Aeromonas infections, supporting their potential use in clinical practice.
- 10 March 2023
- Published by Elsevier in Médecine et Maladies Infectieuses Formation
- Vol. 2 (3) , 142-144
Une association surprenante : dactylite bulleuse distale, bactériémie, pneumopathie et arthrite septique
- 10 March 2023
- Published by Elsevier in Médecine et Maladies Infectieuses Formation
- Vol. 2 (3) , 142-144
Une association surprenante : dactylite bulleuse distale, bactériémie, pneumopathie et arthrite septique
- Open Access
- 28 December 2020
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (12) , e1009152
Role of astroglial Connexin 43 in pneumolysin cytotoxicity and during pneumococcal meningitis
Streptococcus pneumoniaeor pneumococcus (PN) is a major causative agent of bacterial meningitis with high mortality in young infants and elderly people worldwide. The mechanism underlying PN crossing of the blood brain barrier (BBB) and specifically, the role of non-endothelial cells of the neurovascular unit that control the BBB function, remains poorly understood. Here, we show that the astroglial connexin 43 (aCx43), a major gap junctional component expressed in astrocytes, plays a predominant role during PN meningitis. Following intravenous PN challenge, mice deficient for aCx43 developed milder symptoms and showed severely reduced bacterial counts in the brain. Immunofluorescence analysis of brain slices indicated that PN induces the aCx43–dependent destruction of the network of glial fibrillary acid protein (GFAP), an intermediate filament protein specifically expressed in astrocytes and up-regulated in response to brain injury. PN also induced nuclear shrinkage in astrocytes associated with the loss of BBB integrity, bacterial translocation across endothelial vessels and replication in the brain cortex. We found that aCx4-dependent astrocyte damages could be recapitulated usingin vitrocultured cells upon challenge with wild-type PN but not with aplymutant deficient for the pore-forming toxin pneumolysin (Ply). Consistently, we showed that purified Ply requires Cx43 to promote host cell plasma membrane permeabilization in a process involving the Cx43-dependent release of extracellular ATP and prolonged increase of cytosolic Ca2+in host cells. These results point to a critical role for astrocytes during PN meningitis and suggest that the cytolytic activity of the major virulence factor Ply at concentrations relevant to bacterial infection requires co-opting of connexin plasma membrane channels.
- 28 December 2020
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (12) , e1009152
Open AccessRole of astroglial Connexin 43 in pneumolysin cytotoxicity and during pneumococcal meningitis
Streptococcus pneumoniaeor pneumococcus (PN) is a major causative agent of bacterial meningitis with high mortality in young infants and elderly people worldwide. The mechanism underlying PN crossing of the blood brain barrier (BBB) and specifically, the role of non-endothelial cells of the neurovascular unit that control the BBB function, remains poorly understood. Here, we show that the astroglial connexin 43 (aCx43), a major gap junctional component expressed in astrocytes, plays a predominant role during PN meningitis. Following intravenous PN challenge, mice deficient for aCx43 developed milder symptoms and showed severely reduced bacterial counts in the brain. Immunofluorescence analysis of brain slices indicated that PN induces the aCx43–dependent destruction of the network of glial fibrillary acid protein (GFAP), an intermediate filament protein specifically expressed in astrocytes and up-regulated in response to brain injury. PN also induced nuclear shrinkage in astrocytes associated with the loss of BBB integrity, bacterial translocation across endothelial vessels and replication in the brain cortex. We found that aCx4-dependent astrocyte damages could be recapitulated usingin vitrocultured cells upon challenge with wild-type PN but not with aplymutant deficient for the pore-forming toxin pneumolysin (Ply). Consistently, we showed that purified Ply requires Cx43 to promote host cell plasma membrane permeabilization in a process involving the Cx43-dependent release of extracellular ATP and prolonged increase of cytosolic Ca2+in host cells. These results point to a critical role for astrocytes during PN meningitis and suggest that the cytolytic activity of the major virulence factor Ply at concentrations relevant to bacterial infection requires co-opting of connexin plasma membrane channels.